Literature DB >> 7870638

Guideline for the clinical use and dispensing of thalidomide.

R J Powell1, J M Gardner-Medwin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7870638      PMCID： PMC2398010          DOI： 10.1136/pgmj.70.830.901

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN： 0032-5473            Impact factor:   2.401


× No keyword cloud information.
  9 in total

1.  Thalidomide for systemic lupus erythematosus.

Authors:  D F Hawkins
Journal:  Lancet       Date:  1992-04-25       Impact factor: 79.321

2.  Neuropathy after intake of thalidomide (distaval).

Authors:  P M FULLERTON; M KREMER
Journal:  Br Med J       Date:  1961-09-30

3.  Sensory nerve action potentials in patients with peripheral nerve lesions.

Authors:  R W GILLIATT; T A SEARS
Journal:  J Neurol Neurosurg Psychiatry       Date:  1958-05       Impact factor: 10.154

4.  Use of thalidomide in leprosy.

Authors:  C L Crawford
Journal:  BMJ       Date:  1991-06-29

5.  Sensory conduction of the sural nerve in polyneuropathy.

Authors:  D Burke; N F Skuse; A K Lethlean
Journal:  J Neurol Neurosurg Psychiatry       Date:  1974-06       Impact factor: 10.154

6.  Thalidomide neuropathy: a clinical electrophysiological, and histological follow-up study.

Authors:  P M Fullerton; D J O'Sullivan
Journal:  J Neurol Neurosurg Psychiatry       Date:  1968-12       Impact factor: 10.154

7.  An improved technique for radial nerve conduction studies.

Authors:  A W Downie; T R Scott
Journal:  J Neurol Neurosurg Psychiatry       Date:  1967-08       Impact factor: 10.154

8.  Thalidomide treatment for chronic graft-versus-host disease.

Authors:  D Heney; D R Norfolk; J Wheeldon; C C Bailey; I J Lewis; D L Barnard
Journal:  Br J Haematol       Date:  1991-05       Impact factor: 6.998

9.  Thalidomide inhibits the replication of human immunodeficiency virus type 1.

Authors:  S Makonkawkeyoon; R N Limson-Pobre; A L Moreira; V Schauf; G Kaplan
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205
  9 in total
  9 in total

Review 1.  Behçet's disease.

Authors:  V Kontogiannis; R J Powell
Journal:  Postgrad Med J       Date:  2000-10       Impact factor: 2.401

2.  New roles for thalidomide.

Authors:  R J Powell
Journal:  BMJ       Date:  1996-08-17

3.  Guidelines for the clinical use and dispensing of thalidomide.

Authors:  M R Judge; A Kobza-Black; J L Hawk
Journal:  Postgrad Med J       Date:  1995-02       Impact factor: 2.401

Review 4.  Treatment options for juvenile-onset systemic lupus erythematosus.

Authors:  Luis Carreño; Francisco Javier López-Longo; Carlos Manuel González; Indalecio Monteagudo
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

5.  Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial.

Authors:  J N Gordon; T M Trebble; R D Ellis; H D Duncan; T Johns; P M Goggin
Journal:  Gut       Date:  2005-04       Impact factor: 23.059

Review 6.  Treatment of pruritus associated with systemic disorders in the elderly: a review of the role of new therapies.

Authors:  Ann Lonsdale-Eccles; Andrew J Carmichael
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 7.  Thalidomide and its derivatives: emerging from the wilderness.

Authors:  J N Gordon; P M Goggin
Journal:  Postgrad Med J       Date:  2003-03       Impact factor: 2.401

8.  Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer.

Authors:  T Eisen; C Boshoff; I Mak; F Sapunar; M M Vaughan; L Pyle; S R Johnston; R Ahern; I E Smith; M E Gore
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

9.  Thalidomide in dermatology: revisited.

Authors:  Iffat Hassan; Konchok Dorjay; Parvaiz Anwar
Journal:  Indian J Dermatol       Date:  2015 Mar-Apr       Impact factor: 1.494
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.